title: [Intraperitoneal administration of OK-432 and rIL-2 in a case of peritonitis carcinomatosa with chronic renal failure].
abstract: Recombinant interleukin-2 (rIL-2) was administered intraperitoneally for 15 days, 2 days after intraperitoneal administration of Streptococcal preparation OK-432 to a patient of peritonitis carcinomatosa occurred eight months after second look operation, in which residual tumor could not be removed completely. The patient had been maintained by hemodialysis three times a week for over ten years. Combination chemotherapy using CDDP and Ifosfamide, or CDDP and THP-Adriamycin had not been effective to control rapidly increasing ascites. Negative cytological exam, was achieved on day 7 and ascites disappeared by day 15. No severe side effects including fluid retention were observed. Fever up was controllable by Indomethacin. Flow cytometric analysis revealed dominant (73%) CD4+, CD29+ helper inducer subset, while CD4+, CD45RA+ was 6%, in the lymphocytes in ascites on day 8. It was suggested that intraperitoneal administration of rIL-2 after OK-432 was safe and effective for peritonitis carcinomatosa with chronic renal failure.
authors.affiliation: Department of Obstetrics and Gynecology, Osaka City University Medical School.
authors.forename: Y
authors.initials: Y
authors.lastname: Kanaoka
authors.forename: N
authors.initials: N
authors.lastname: Umesaki
authors.forename: M
authors.initials: M
authors.lastname: Kawabata
authors.forename: H
authors.initials: H
authors.lastname: Tsuda
authors.forename: T
authors.initials: T
authors.lastname: Sugawa
mesh_terms: D000230:Adenocarcinoma / Q000209:etiology / Q000556:secondary* / Q000628:therapy; D000328:Adult; D001688:Biological Products / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007116:Immunization, Passive; D007263:Infusions, Parenteral; D007376:Interleukin-2 / Q000008:administration & dosage / Q000627:therapeutic use*; D007676:Kidney Failure, Chronic / Q000150:complications*; D015979:Killer Cells, Lymphokine-Activated; D010051:Ovarian Neoplasms; D010534:Peritoneal Neoplasms / Q000209:etiology / Q000556:secondary* / Q000628:therapy; D010844:Picibanil / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D001688:Biological Products; D007376:Interleukin-2; D010844:Picibanil